Premium
Inside Cover: Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3 H )‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation (ChemMedChem 5/2014)
Author(s) -
Diab Sarah,
Teo Theodosia,
Kumarasiri Malika,
Li Peng,
Yu Mingfeng,
Lam Frankie,
Basnet Sunita K. C.,
Sykes Matthew J.,
Albrecht Hugo,
Milne Robert,
Wang Shudong
Publication year - 2014
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201490016
Subject(s) - cover (algebra) , p38 mitogen activated protein kinases , protein kinase b , chemistry , kinase , mapk/erk pathway , apoptosis , pi3k/akt/mtor pathway , cancer research , drug discovery , computational biology , potency , combinatorial chemistry , biochemistry , biology , in vitro , engineering , mechanical engineering
The inside cover picture shows the unique opportunity offered by Mnk inhibitors in simultaneously targeting the Ras/Raf/Erk, MKK/p38 and Akt/mTOR/eIF4E pathways in human cancers. The compound shown targets Mnk2 with low nanomolar potency, and is capable of abrogating anti‐apoptotic protein Mcl‐1 and inducing apoptosis in MV4‐11 leukemia cells. For further details, see the Full Paper by Shudong Wang et al. on p. 962 ff.